This autumn, Adelphi Research explored two of the biggest healthcare conferences, ESMO 2025 and EASD 2025, capturing agile insights from healthcare professionals and uncovering the key trends shaping oncology and diabetes care. Our post-conference surveys reveal what really captured attention, sparked excitement and could influence clinical practice.
European Society for Medical Oncology (ESMO) 2025
At ESMO 2025, our post-conference survey highlighted which companies and trials generated the most excitement among attendees:
- Conference Buzz: AstraZeneca and Daiichi-Sankyo led the way, for AstraZeneca this was largely due to pivotal trial data in breast cancer. Notable readouts included DESTINY-Breast05/11 and FLAURA2.
- Best Experience: AstraZeneca also stood out for providing the best overall conference experience, followed closely by BMS and Daiichi-Sankyo.
- Practice Impact: Breast cancer results were identified as having the highest potential to influence clinical practice, with 72% of HCPs noting the significance of these findings.
Other areas generating notable excitement included MIBC and NSCLC, with AstraZeneca’s presence being particularly strong across multiple tumour types and next-gen modalities.
Meanwhile, at EASD 2025, our post-conference survey captured the growing interest in diabetes, obesity and cardiovascular care:
- Conference Buzz: Novo Nordisk (73%) and Eli Lilly (64%) generated the highest excitement among attendees, thanks to high-profile GLP-1 developments and SURPASS trial readouts.
- Session Engagement: Sessions on GLP-1 therapies and SURPASS trials had the highest engagement:
- 71% engaged with the latest GLP-1 developments
- 64% focused on the SURPASS-CVOT comparing tirzepatide and dulaglutide in T2D with cardiovascular risk
- 64% engaged with tirzepatide, about breaking barriers in weight management, T2D and OSA
- 63% explored semaglutide’s effects in peripheral artery disease and type 2 diabetes (STRIDE trial)
Mounjaro was particularly high on the excitement scale, reflecting a keen appetite among HCPs for innovation in metabolic health.
Major conferences like ESMO and EASD don’t just report the present – they signal the future of clinical practice. Our post-conference surveys can capture leading indicators of market shifts. For pharma teams, these insights can answer critical questions and shape future strategy. For more insights from Adelphi Research’s post-conference surveys or to explore bespoke research strategies for your brand:
Contact: Pam Hallworth – [email protected] (UK), Ben Walker – [email protected] (UK) or Amy Gilpin – [email protected] (US)